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Summary All-trans-retinoic acid (RA), like insulin-like growth factor I (IGF-I) and tamoxifen, inhibit
invasion of human MCF-7/6 mammary cancer cells in vitro. For tamoxifen and for IGF-I, activation of the
invasion-suppressor function of the E-cadherin/catenin complex was shown to be the most probable
mechanism of the anti-invasive action. We did a series of experiments to determine whether the anti-invasive
effect of RA also implicated the invasion-suppressor E-cadherin/catenin complex. Human MCF-7/6 mammary
and HCT-8/R1 colon cancer cells, both with a dysfunctional E-cadherin/catenin complex, were treated with
RA and the function of the complex was evaluated through Ca2+-dependent fast aggregation. Fast aggrega-
tion of both MCF-7/6 and HCT-8/RI cells was induced by 1 gtM RA. This effect was abolished by antibodies
against E-cadherin. RA-induced fast aggregation was not sensitive to cycloheximide, tyrosine kinase inhibitors
or antibodies against IGF-I or against the IGF-I receptor. RA did not stimulate IGF-I receptor phosphoryla-
tion or alter the E-cadherin/catenin complex, as evidenced by immunoprecipitation. RA up-regulates the
function of the invasion-suppressor complex E-cadherin/catenin. Its action mechanism is different from that
of IGF-I. RA may act as an anti-invasive agent with unique mechanisms of action.
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The epithelial Ca2+-dependent cell-cell adhesion molecule
E-cadherin has an invasion-suppressor function when linked
to the actin cytoskeleton via a-catenin plus P-, or y-catenin
(Takeichi, 1993; Mareel et al., 1994). The adhesive function
of the E-cadherin/catenin complex can be down-regulated at
the transcriptional, translational and post-translational level
in experimental (Shimoyama et al., 1992; Behrens et al.,
1993) and in human (Bringuier et al., 1993) cancer. Recently,
the APC protein has been implicated in the regulation of the
E-cadherin/catenin complex through association with a- and
P-catenin in the cytoplasm (Su et al., 1993). Furthermore,
new models have been described for the homophilic interac-
tions between the extracellular domains of cadherins (Over-
duin et al., 1995; Shapiro et al., 1995). Experiments both in
vivo (Mareel et al., 1991) and in vitro (Van Roy et al., 1992;
Bracke et al., 1993) have suggested that the invasion-
suppressor function of the E-cadherin/catenin complex is
modulated by external factors. In human MCF-7/6 breast
cancer cells IGF-I (Bracke et al., 1993) and the anti-estrogen
tamoxifen (Bracke et al., 1994a) up-regulated the adhesive
function of the E-cadherin/catenin complex and inhibited
invasion in vitro. Inhibition of invasion of MCF-7/6 cells was
also obtained with RA (Bracke et al., 1991). We therefore
wanted to examine whether RA could up-regulate the
adhesive function of the E-cadherin/catenin complex. We
have also examined the effect of RA on the components of
the E-cadherin/catenin complex, using immunoprecipitation
of metabolically labelled. cells. Finally, since the literature
mentions that RA modulates IGF-I as well as IGF-binding
proteins (IGFBPs) (Fontana et al., 1991; Figueroa and Yee,
1992), we have tested possible relationships between IGF-I-
mediated regulation of E-cadherin/catenin functions and
effects of RA. The general purpose of our work is to find
agents that activate invasion-suppressor molecules and are
therefore candidates for chronic anti-invasive treatment of
cancer.
Materials and methods
Cells
The MCF-7/6 cell line (obtained from Dr H Rochefort,
Unite d'Endocrinologie Cellulaire et Moleculaire, Montpel-
lier, France) is a variant of the human MCF-7 breast cancer
cell family. MCF-7/6 cells were treated with 1 jig ml-'
mycoplasma removal agent (ICN Biomedicals, Costa Mesa,
CA, USA) for seven passages. For the present experiments
the cells were harvested from mycoplasma-free stock cultures
maintained as described previously (Bracke et al., 1991). The
HCT-8/R1 cell line is a subclone from the human HCT-8
colon cancer cell line (CCL244, ATCC, Rockville, MD,
USA) that was selected for its round morphotype. HCT-8/R1
cells were maintained in RPMI-1640, supplemented with
1 mM sodium pyruvate and 100 fig ml-1 streptomycin. MCF-
7/6 (Bracke et al., 1991, 1993) and HCT-8/R1 cells
(Vermeulen et al., 1994) are invasive and have a dysfunc-
tional E-cadherin/catenin complex, i.e. unable to mediate fast
Ca2 +-dependent homotypic aggregation. MDA-MB-231
(ATCC; HTB26) cells were maintained in Leibovitz-15
medium, supplemented with 0.05% glutamine. These cells do
not express E-cadherin (Frixen et al., 1991). All culture
media (Gibco, Gent, Belgium) were supplemented with 10%
fetal bovine serum (FBS) and 250 IUml-' penicillin.
Drugs
All-trans-retinoic acid (RA; Sigma, St Louis, MO, USA) was
dissolved in ethanol at 1 mM and used at concentrations
between 0.1 nM and 1 iLM. Control cultures were treated with
corresponding ethanol concentrations. To study the role of
de novo protein synthesis cells were treated with cyclohex-
imide (Sigma) at 1Olg ml-. Recombinant human IGF-I was
from Boehringer Mannheim (Brussels, Belgium). As tyrosine
kinase inhibitors (all from Gibco) we used Genistein (25AM),
Me-2,5-dihydroxycinnamate (50AtM), RCAM-lysozyme (1 ALM)
and 2-OH-5-(2,5-diOH-benzyl)aminobenzoic acid (10ylM).
Treatment schedules are mentioned in the Results section.
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Antibodies
MB2 (Bracke et al., 1993) and HECD-1 (Takara Shuzo,
Kyoto, Japan) are monoclonal antibodies against human
E-cadherin with neutralising effects on E-cadherin functions
(Bracke et al., 1993). aIR3 and 82-9A (Oncogene Science,
Uniondale, NY, USA), are monoclonal antibodies func-
tionally blocking respectively the human IGF-I receptor
(Cullen et al., 1990; Bracke et al., 1993) and human IGF-I
(Kerr et al., 1990). PY20 (ICN Biomedicals) is a monoclonal
antibody recognising phosphotyrosine. 5D10 (obtained from
Dr L Plessers, Limburgs Universitair Centrum, Diepenbeek,
Belgium), is a monoclonal antibody against MCF-7 cell sur-
face components (Plessers et al., 1986). Anti CEA (Dako-
patts, Glostrup, Denmark), a purified immunoglobulin frac-
tion of rabbit antiserum, reacts with CEA and CEA-like
molecules. We prepared rabbit anti-p-catenin antiserum using
as an immunogen a synthetic peptide C-PGDSNQLAW-
FDTDL (provided by J Vandekerckhove, Laboratory of
Physiological Chemistry, University of Gent, Gent, Belgium)
corresponding to the C-terminal part of mouse P-catenin
(Butz et al., 1992). The peptide was coupled on keyhole
limpet haemocyanin via the additional N-terminal cysteine
and used for four cycles of intradermal and intramuscular
immunisation of rabbits. Immune serum was affinity purified
by fast protein liquid chromatography (FPLC) (Pharmacia,
Uppsala, Sweden) with the peptide bound to a p-hydroxy-
mercuribenzoate matrix (Sigma). Immune serum 1522 recog-
nised a 95 kDa band on Western blots and immuno-
precipitated from metabolically labelled cell lysates the 95,
102 and 120 kDa bands that are specific for the E-cadherin/
catenin complex.
Assayforfast aggregation
Cell-cell adhesion was numerically evaluated in an aggrega-
tion assay as described (Bracke et al., 1993). Briefly, cells
were detached in E-cadherin-saving conditions and allowed
to aggregate on a Gyrotory shaker (New Brunswick
Scientific, New Brunswick, NJ, USA) in a buffer containing
1.25 mM Ca2+ and 0.1% bovine serum albumin. The agg-
regation index was expressed as 1 - N30/No, where No
indicates the initial number of particles and N30 the number
of particles after 30 min present in a constant volume of
500fil. The number of particles was measured by a Coulter
counter ZM (Coulter, Miami, FL, USA) with the following
settings: full scale, 10 mA; current, 3.34 mA; lower threshold,
5.0 JAM; attenuation, 32; preset gain, 2; aperture size, 140 JAm.
Aggregate size distribution in function of volume % (total
volume of all aggregates equals 100%) was analysed on
20 000 particles by a Coulter MultisizerIle with the following
settings: current, 3.2 mA; lower threshold, 8.0 JAM; preset
gain, 1; aperture size, 400 JAm.
aggregation and lysed after 10 min using the lysis buffer
described previously with the following protease inhibitors
(all from Sigma): phenylmethylsulphonyl fluoride (1.72 mM),
leupeptin (21 JiM), aprotinin (10 fig ml-'). Equal amounts of
trichloroacetic acid-precipitable material were precleared for
30 min at 4°C with 25Jl protein G sepharose 4 fast flow
(Pharmacia). HECD-1 (1 fig per precipitation) or immune
serum 1522 (201AI per precipitation) followed by protein G
sepharose 4 fast flow were used for co-immunoprecipitation.
The immune complexes were washed three times with 750Jl
of lysis buffer. Proteins were eluted by sodium dodecyl sul-
phate under reducing conditions and analysed by sodium
dodecyl sulphate polyacrylamide (6%) gel electrophoresis fol-
lowed by fluorography.
Molecular characterisation ofIGF-I receptor andbinding
proteins
The IGF-I receptor phosphorylation was evaluated by
sequential immunoprecipitation as described by Izumi et al.
(1987) with the following modifications. Cells were washed
three times in phosphate-free EMEM with 2% dialysed FBS
(Gibco) followed by labelling with 0.5mCiml-I carrier-free
[32P]orthophosphate (Amersham, Gent, Belgium) for 2 h.
Cells were lysed in the presence of the following phosphatase
inhibitors (all from Sigma): sodium pyrophosphate (10 mM);
sodium fluoride (10 mM); sodium vanadate (1 mM). Phos-
photyrosine molecules were immunoprecipitated with PY20
(5 fig per precipitation), immune complexes were washed
three times with 750 l of lysis buffer and molecules were
eluted three times for 15 min with 250 lal elution buffer con-
taining: phospho-L-tyrosine (10 mM) and phenylphosphate
(10 mM) in lysis buffer. Eluted molecules were immuno-
precipitated with aIR3 (1 jig per precipitation) and proteins
were analysed as described with the E-cadherin/catenin com-
plex. IGFBPs were evaluated by ligand blotting (Fontana et
al., 1991). Briefly, cells were washed 5 times with serum-free
medium followed by incubation for 44 h in the same
medium. The conditioned medium was dialysed against
1.5 mM Tris and concentrated 100 times by lyophilisation.
Lyophilised proteins were denatured with sodium dodecyl
sulphate under non-reducing conditions, separated on 12%
polyacrylamide gels and electroblotted. IGFBPs were visu-
alised by ['251IlGF-I (Hossenlopp et al., 1986). We quan-
titated IGFBPs with an XRS 12cx Omnimedia scanner using
Bio Image Whole Band Analyser software (Millipore, Etten-
Leur, The Netherlands) on a Sun Sparc Classic computer.
n rn-
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Flow cytometric analysis ofE-cadherin
MCF-7/6 cells, detached as in the assay for fast aggregation,
were incubated with the antibody against E-cadherin
(HECD-1) followed by rabbit anti-mouse antiserum con-
jugated with fluoresceine isothiocyanate (RAM-FITC,
Dakopatts) as a second antibody (Bracke et al., 1993).
Fluorescence intensity was measured with a FACScan III
(Becton Dickinson, Mountain View, CA, USA).
Molecular characterisation ofthe E-cadherin/catenin complex
The E-cadherin/catenin complex was characterised by co-
immunoprecipitation from metabolically labelled cells as des-
cribed (Vleminckx et al., 1994) with the following
modifications. Cells on plastic tissue culture substrate were
washed three times in methionine-free Eagle's minimum
essential medium (EMEM, Gibco) with 2% dialysed FBS
(Gibco) followed by incubation for 30 min in the same
medium and addition of 100 JACi ml 'Tran35S (ICN Bio-
medicals) for 3 h. Cells were detached as in the assay for fast
Z 0.30
0.20
0.10
0.00 LJL"
Ca2+ - + + + +
RA +a +b +b
Antibody - - +
MCF-7/6
- + +
-+a +b +b
H -/R
HCT-8/R1 MDA-MB-231
+a +b +b
Figure 1 Fast aggregation (1 - N31No) of MCF-7/6, HCT-8/RI
and MDA-MB-231 cells with (+) or without (-) Ca2". Cells
were treated with RA at I iAM ( + ) or with solvent (-) for 4 (a)
or 24 h (b) and the agent was present during aggregation. Cells
were pretreated for 30 min at 4'C with( + ) or without (-) the
E-cadherin-specific antibody MB2 or HECD-1 (diluted 1:20) and
the antibodies remained present during aggregation. Bars repre-
sent mean values + s.d. of six measurements.
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MCF-7/6 cells showed a poor tendency to aggregate in accor-
dance with previous results (Bracke et al., 1993). Pretreat-
ment of cells with RA at 1 fLM induced Ca2+-dependent and
E-cadherin-specific fast aggregation of MCF-7/6 cells (Figure
1). Analysis of aggregate size distribution showed formation
of larger aggregates in RA-treated than in untreated samples
(Figure 2). The effect of RA was counteracted by an
antibody against E-cadherin (Figure 2). The minimum dura-
tion of treatment needed for maximum effect was 4 h. Partial
response was obtained within 2 h of treatment at a concent-
ration of 1 ,LM RA or within 24 h treatment at 0.1 1M (Figure
a
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6
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3). RA also induced E-cadherin-specific fast aggregation in
HCT-8/R1 cells lacking a-catenin, although to a lesser extent
than in MCF-7/6 cells (Figure 1). The E-cadherin-negative
MDA-MB-231 cells showed Ca2+-independent fast aggrega-
tion that was hardly altered by RA or by an antibody against
E-cadherin (Figure 1). RA-induced fast aggregation of MCF-
7/6 cells was not inhibited by cycloheximide at concentra-
tions that reduced Tran35S incorporation to less than 15% of
untreated controls (Figure 4). It was lowered by antibodies
functionally blocking E-cadherin but not by antibodies
against other surface molecules, (Figure 5) shown to be
expressed on MCF-7/6 cells by Western blots (CEA, SD10;
data not shown). Neither did RA-induced fast aggregation
respond to antibodies against IGF-I or IGF-I receptor
(Figure 5) in matched experiments in which IGF-I-induced
aggregation was clearly inhibited (data not shown). RA
changed neither the level of E-cadherin expressed at the cell
surface as revealed by flow cytometry (Figure 6) nor the
composition of the E-cadherin/catenin complex in MCF-7/6
cells (Figure 7). IGF-I receptor phosphorylation was not
increased by RA in contrast to the effect of IGF-I (Figure 8).
Neither was RA-induced fast aggregation inhibited by the
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Figure 2 Aggregate size distribution of RA-induced fast agg-
regation of MCF-7/6 cells. Approximately 20 000 particles were
analysed before (E) and after 30 min (*) of aggregation. Cells
were treated (b and c) or not (a) with I ILM RA for 24.5 h,
including the time of aggregation. Cells were pretreated (c) for
1 h at 4°C with the E-cadherin-specific antibody MB2 (diluted
1:20) and the antibodies remained present during aggregation.
Ordinate, percentage of total volume of aggregates; abscissa, size
of aggregates in 1tm.
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Figure 3 RA-induced fast aggregation (1 - N30/NO) of MCF-7/6
cells as a function of RA concentration (a) and time of RA
treatment (b). (a) Treatment with RA (concentration in AM) for
24.5 h including the time of aggregation. (b) Treatment with 1 A4M RA (time in h). Bars represent mean values + s.d. of six
measurements.
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Figure 4 Fast aggregation (1 - N30/NO; open bars) and Tran35S
incorporation (percentage of untreated; hatched bars) by MCF-7/
6 cells pretreated ( + ) or not (-) with 10 ptg ml- cycloheximide
for 5 h and with fiM RA ( + ) or with solvent (-) during the
last 4 h; when cycloheximide and RA were added, they were also
present during the aggregation assay. Bars represent mean
values + s.d. of six measurements.
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Figure 5 RA-induced fast aggregation (1 - N30/NO) of MCF-7/6
cells in the presence of antibodies against E-cadherin (HECD-1,
1:20), CEA (anti-CEA, 1:100), an unidentified MCF-7 cell surface
epitope (5Dl0, 1:10), the IGF-I receptor (aIR3; 15i.gml-') or
IGF-I (82-9A, 15pgml-'). Treatment with RA (1I M) was for
4.5h including the time of aggregation. Cells were pretreated
with antibodies for 5 h (82-9A or aIR3) at 37°C or for 30 min (all
other antibodies) at 4°C and antibodies remained present during
aggregation. Bars represent mean values + s.d. of six
measurements.
tyrosine kinase inhibitors Genistein (25 tiM), Me-2,5-dihy-
droxycinnamate (50 tiM), RCAM-lysozyme (1 tIM) or 2-OH-
5-(2,5-diOH-benzyl)aminobenzoic acid (10 tiM) (Table I),
although such concentrations inhibited IGF-I-induced fast
aggregation (Bracke et al., 1994b). The total amount of
IGFBPs in medium conditioned for 44 h from MCF-7/6 cells
treated with RA at 0.1 tIM was 1.1 and 1.5 times (two
independent experiments) higher than in medium from un-
treated cultures.
Figure 6 Flow cytometric analysis of E-cadherin expression in
MCF-7/6 cells treated (b) or not (a) with 1 tLM RA for 4 h. The
anti-E-cadherin antibody HECD-1 (1:20) was used (open area) or
not (shaded area) as first antibody; RAM-FITC was used (1:20)
as second antibody. Ordinate, number of cells; abscissa,
fluorescence intensity.
Discussion
We report that RA, at anti-invasive concentrations, induces
fast aggregation of cells which have a dysfunctional E-
cadherin/catenin complex. This induction was prevented by
monoclonal antibodies that functionally blocked E-cadherin
but not by other antibodies also binding to the cell surface.
For MCF-7/6 breast cancer cells, induction of E-cadherin-
dependent fast aggregation was achieved also with IGF-I
(Bracke et al., 1993), with tamoxifen (Bracke et al., 1994a)
and with the citrus flavonoid tangeretin (Bracke et al.,
1994b). All these agents inhibited invasion of MCF-7/6 cells
in organ culture confirming the invasion-suppressor function
of the E-cadherin/catenin complex (Mareel et al., 1994). E-
cadherin is known to act as an organiser ofjunctional com-
plexes. It might be that the rapid and reversible cell type- and
concentration-related up- or down-modulation of gap-junc-
tional communication by RA (Mehta et al., 1989) occurs via
modulation of the E-cadherin/catenin complex. Induction of
the epithelioid morphotype and of E-cadherin expression at
the cell-cell contact sites was reported with human SK-BR-3
mammary cancer cells treated with RA (Anzano et al., 1994).
RA-induced fast aggregation also occurred in the absence
of de novo protein synthesis, as demonstrated by our
experiments with cycloheximide. This suggests that RA, in
association with its receptors or not, interacts directly with
the E-cadherin/catenin complex or its effectors. It does not,
however, exclude the possibility that RA acts via binding to
hormone-sensitive elements, leading to arrest of transcription
of an inhibitory protein. The fact that cycloheximide by itself
has no effect on fast aggregation argues against the latter
possibility.
The relatively high concentrations (1-0.1 M) of RA
needed to induce fast aggregation are similar to those des-
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cribed for the decrease in B16 melanoma cell aggregation
(Edward et al., 1992) and for down-regulation ofP4 integrins
in LL4 cells (Gaetano et al., 1994). This need may be asc-
ribed to the presence of serum in the culture medium and of
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albumin in the salt solution used for the aggregation assay
(see Materials and methods). Albumin is known to bind RA
as it serves as its carrier protein in the blood (Allen and
Bloxham, 1989).
Our co-immunoprecipitation data failed to demonstrate an
effect of RA on the composition of the E-cadherin/catenin
complex. This observation suggests that the cause ofdysfunc-
tion of E-cadherin in MCF-7/6 cells is situated downstream
of the E-cadherin/catenin complex. The fact that RA also
induced E-cadherin-dependent fast aggregation, although less
effectively, in x-catenin-deficient HCT-8/R1 cells supports the
idea of a downstream defect in MCF-7/6 cells.
RA does not seem to interact directly with IGFBPs, IGF-I
or the IGF-I receptor, all of which are implicated in IGF-I-
mediated aggregation of MCF-7/6 cells (Bracke et al., 1993).
An action via an autocrine IGF-I loop is unlikely because
antibodies functionally blocking IGF-I did not hamper RA-
induced aggregation. Neither could it be inhibited with
antibodies against the IGF-I receptor nor did phosphoryla-
tion of the IGF-I receptor occur upon RA treatment in
contrast to addition of IGF-I. Moreover, the tyrosine kinase
inhibitors that blocked IGF-I-induced fast aggregation had
no effect on RA-induced aggregation. It is unlikely that the
slight increase in IGFBPs found in our and in others'
experiments (Fontana et al., 1991; Yee et al., 1994) was
involved in RA-induced aggregation, since such an increase
would have had an opposite effect. Indeed, IGFBPs are
known to neutralise IGF-I and a variant of IGF-I lacking
the IGFBP-binding domain was much more potent than
genuine IGF-I at inducing fast aggregation (Bracke et al.,
1994b).
Our present results indicate that activation of the E-
cadherin/catenin complex may contribute to the anti-invasive
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Figure 7 Autoradiographs of sodium dodecyl sulphate polyac-
rylamide gel electropherograms from total lysates of MCF-7/6
cells metabolically labelled with Tran35S and immunoprecipitated
with the E-cadherin-specific antibody HECD-1 (top), with the
rabbit anti-1-catenin antiserum 1522 (middle) or without anti-
body (bottom). MCF-7/6 cells were treated for 2 h with I JAM RA
(lane 1), with solvent (lane 2) or untreated (lane 3). E-CAD,
E-cadherin; a-CTN, a-catenin; P-CTN, P-catenin; y-CTN, y-
catenin. Horizontal bars (right) indicate molecular weight
markers.
Figure 8 Autoradiograph of sodium dodecyl sulphate polyac-
rylamide gel electropherogram from total lysates of MCF-7/6
cells metabolically labelled with 32P and sequentially immuno-
precipitated with respectively, a phosphotyrosine specific anti-
body (PY20) and an IGF-I receptor specific antibody (aIR3).
MCF-7/6 cells were treated for 4 h with 1 JLM RA (lane 1), with
250 JM acetic acid (solvent of IGF-1, lane 2) or 0.5 gml-l
IGF-I (lane 3). 1, P-Subunit of the IGF-I receptor. Horizontal
bars (right) indicate molecular weight markers.
Table I Fast aggregation of MCF-7/6 cells
1 -
Treatmenta RAC IGF-Id
None 0.469 + 0.004 0.274 ± 0.005
10gM 2-OH-5-[2,5-diOH-benzyl] 0.487 ± 0.014 0.015 + 0.003
aminobenzoic acid
1 tLM RCAM-lysozyme 0.456 + 0.019 0.038 ± 0.008
50ILM Me-2,5-diOH-cinnamate 0.613 + 0.020 0.041 ± 0.013
25gM Genistein 0.633 ± 0.007 0.033 ± 0.006
(a) Cells were treated with tyrosine kinase inhibitors I h preceding and during RA or IGF-1
treatment. (b)Aggregation index, numerical valuesindicatemean ± s.d. ofsixmeasurements.
Cells were treated with (C) 1 JLM RA for 4.5 h or (d) 0.5figml-' IGF-I for 30 min. In the
absence of either tyrosine kinase inhibitor, RA or IGF-I, MCF-7/6 aggregation was:
0.080 ± 0.008 (mean ± s.d. of six measurements).
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activity of RA on MCF-7/6 cells as described previously
(Bracke et al., 1991). It is, however, unlikely that this is the
only mechanism of the anti-invasive action of RA. Such
action was described also for melanoma (Helige et al., 1993)
and rhabdomyosarcoma (Gerharz et al., 1993) cells which are
not expected to express E-cadherin. RA did not inhibit,
however, the invasion of the E-cadherin-negative MDA-MB-
231 cells into chick heart (our unpublished results). This
shows the existence of alternative mechanisms of anti-
invasiveness such as inhibition of proteolytic enzymes (Gudas
et al., 1994; Yamamoto et al., 1995).
Taken together, our results indicate that RA-induced agg-
regation of MCF-7/6 cells via the E-cadherin/catenin com-
plex depends upon a mechanism other than IGF-I-induced
aggregation. This novel function, namely the activation of a
dysfunctional E-cadherin/catenin complex via a protein
synthesis-independent mechanism, might identify RA as a
potential anti-invasive agent for combinatorial cancer treat-
ment.
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